Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy CRISPR Therapeutics stock
Learn how to easily invest in CRISPR Therapeutics stock.
CRISPR Therapeutics AG is a biotechnology business based in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. CRISPR Therapeutics employs 410 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in CRISPR Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CRSP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
CRISPR Therapeutics stock price (NASDAQ: CRSP)Use our graph to track the performance of CRSP stocks over time.
CRISPR Therapeutics shares at a glance
|Latest market close||$62.61|
|52-week range||$62.21 - $191.10|
|50-day moving average||$76.40|
|200-day moving average||$108.24|
|Wall St. target price||$149.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.26|
Buy CRISPR Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CRISPR Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CRISPR Therapeutics price performance over time
|1 week (2022-01-13)||-5.71%|
|1 month (2021-12-23)||-23.79%|
|3 months (2021-10-20)||N/A|
|6 months (2021-07-23)||-48.79%|
|1 year (2021-01-22)||-66.78%|
|2 years (2020-01-24)||14.36%|
|3 years (2019-01-24)||93.90%|
|5 years (2017-01-24)||230.40%|
Is CRISPR Therapeutics stock undervalued or overvalued?
Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CRISPR Therapeutics's P/E ratio
CRISPR Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, CRISPR Therapeutics shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
CRISPR Therapeutics's EBITDA
CRISPR Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $425.7 million.
The EBITDA is a measure of a CRISPR Therapeutics's overall financial performance and is widely used to measure a its profitability.
CRISPR Therapeutics financials
|Revenue TTM||$902.4 million|
|Operating margin TTM||45.6%|
|Gross profit TTM||$-266,227,000|
|Return on assets TTM||11.94%|
|Return on equity TTM||21.36%|
|Market capitalisation||$4.8 billion|
TTM: trailing 12 months
CRISPR Therapeutics share dividends
We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.
Have CRISPR Therapeutics's shares ever split?
CRISPR Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before before the split, the next day you'd have owned 333333 shares. This wouldn't directly have changed the overall worth of your CRISPR Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for CRISPR Therapeutics shares which in turn could have impacted CRISPR Therapeutics's share price.
CRISPR Therapeutics share price volatility
Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as $62.21 up to $191.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 2.0471. This would suggest that CRISPR Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CRISPR Therapeutics overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc.
CRISPR Therapeutics in the news
What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020
Is CRISPR Therapeutics a Buy?
Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more
Frequently asked questionsWhat percentage of CRISPR Therapeutics is owned by insiders or institutions?
Currently 5.591% of CRISPR Therapeutics shares are held by insiders and 54.5% by institutions. How many people work for CRISPR Therapeutics?
Latest data suggests 410 work at CRISPR Therapeutics. When does the fiscal year end for CRISPR Therapeutics?
CRISPR Therapeutics's fiscal year ends in December. Where is CRISPR Therapeutics based?
CRISPR Therapeutics's address is: Baarerstrasse 14, Zug, Switzerland, 6300 What is CRISPR Therapeutics's ISIN number?
CRISPR Therapeutics's international securities identification number is: CH0334081137 What is CRISPR Therapeutics's CUSIP number?
CRISPR Therapeutics's Committee on Uniform Securities Identification Procedures number is: H17182108
More guides on Finder
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert